Loading.
Preparing your Shotlee experience
Authenticating
Loading health data
Syncing preferences
Health
Novo Nordisk India Introduces Ozempic, Considering Socio-Economic Factors | Briefs
S
Shotlee
Health & Wellness Team
1 min read
Preparing your Shotlee experience
Novo Nordisk has officially launched Ozempic in India, a once-weekly GLP-1 receptor agonist for adults managing uncontrolled type 2 diabetes. Intended as an add-on therapy to diet and exercise, Ozempic arrives as India grapples with a rapidly increasing diabetes burden and generalized obesity.
Novo Nordisk has officially launched Ozempic (injectable semaglutide) in India. This marks the availability of a widely used once-weekly GLP-1 receptor agonist for adults dealing with uncontrolled type 2 diabetes. The company stated that Ozempic® is designed to supplement diet and exercise, arriving at a crucial time for India, which is experiencing a surge in diabetes cases.
According to WHO's 2023-24 estimates, India has 101 million individuals living with diabetes. An additional 136 million are classified as prediabetic, and 254 million are affected by generalized obesity. These figures underscore the pressing need for effective treatment solutions. Health tracking apps like Shotlee can help monitor blood sugar levels and medication adherence.
Novo Nordisk India MD Vikrant Shrotriya pointed out that many patients face the dual challenge of diabetes and excess weight, making Ozempic a suitable therapeutic option. He also noted that the company is aware of India's socioeconomic realities. To improve accessibility, the medication has been priced at Rs 2,200 per week.
⚠️ Disclaimer: This article is for informational purposes only. Consult your healthcare provider before starting any medication or supplement.
Original content from The Times of India
View Original Article
New data indicates that the State spent almost €2.63 million on the diabetes medication Ozempic in the Shannonside area from January to August of this year. Longford and Westmeath had the highest expenses, totaling about €1.4 million.
A recent study indicates a possible connection between GLP-1 drugs and a reduced risk of epilepsy in individuals with type 2 diabetes. The research, published in Neurology, provides preliminary evidence of neurological advantages from these medications. Larger trials are necessary to confirm these findings.
Recent research highlights a growing trend of British men turning to weight loss injections. Data indicates a significant shift in usage, with men increasingly adopting these treatments.
Monitor GLP-1 medications, peptide therapy, weight loss, and wellness metrics with our comprehensive health tracking app. Join thousands of users taking control of their health!
Start Tracking Free Forever! ✨